Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicentre randomised double masked study

Tariq Aslam, Adnan Tufail, Praveen J. Patel, Catherine Egan, Philip Hykin, Lyndon Da Cruz, Zdenek Gregor, Jonathan Dowler, Mohammed A. Majid, Clare Bailey, Quresh Mohamed, Robert Johnston, Catey Bunce, Wen Xing

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objectives: To evaluate the efficacy and safety of intravitreous bevacizumab injections for the treatment of neovascular age related macular degeneration. Design: Prospective, double masked, multicentre, randomised controlled trial. Setting: Three ophthalmology centres in the United Kingdom. Participants: 131 patients (mean age 81) with wet age related macular degeneration randomised 1:1 to intervention or control. Interventions: Intravitreous bevacizumab (1.25 mg, three loading injections at six week intervals followed by further treatment if required at six week intervals) or standard treatment available at the start of the trial (photodynamic treatment with verteporfin for predominantly classic type neovascular age related macular degeneration, or intravitreal pegaptanib or sham treatment for occult or minimally classic type neovascular age related macular degeneration). Main outcome measures: Primary outcome: proportion of patients gaining ≥15 letters of visual acuity at one year ( 54 weeks). Secondary outcomes: proportion of patients with stable vision and mean change in visual acuity. Results: Of the 131 patients enrolled in the trial, five patients did not complete the study because of adverse events, loss to follow-up, or death. In the bevacizumab group, 21 (32%) patients gained 15 or more letters from baseline visual acuity compared with two (3%) in the standard care group (P
    Original languageEnglish
    Article numberc2459
    Pages (from-to)1398
    JournalBmj
    Volume340
    Issue number7761
    DOIs
    Publication statusPublished - 26 Jun 2010

    Fingerprint

    Dive into the research topics of 'Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicentre randomised double masked study'. Together they form a unique fingerprint.

    Cite this